Abstract
We report a possible association between ruxolitinib and JC virus meningitis. A 72-year-old man with myelofibrosis started treatment with ruxolitinib. Fourteen days later, the patient presented to the emergency department with fever and nausea. HIV test was negative. Ruxolitinib was suspended. Symptoms progressed with neck stiffness, cognitive impairment, and motor aphasia. CSF was positive for JC virus. MRI showed nonspecific abnormal findings. Five days after the clinical debut, the patient died. The clinical picture, MRI imaging, and positive JC virus PCR in CSF strongly suggest ruxolitinib-related JC virus meningitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agnihotri SP, Wutrich C, Dang X, Nauen D, Karimi R, Viscidi R, Bord E, Batson S, Troncoso J, Koralnik IJ (2014) A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann Neurol 76:140–147. doi:10.1002/ana.24192
Bag AK, Curé JK, Chapman PR, Roberson GH, Shah R (2010) JC virus infection of the brain. Am J Neuroradiol 31:1564–1576. doi:10.3174/ajnr.A2035
Dang X, Wüthrich C, Gordon J, Sawa H, Koranik IJ (2012) JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS One 7:1–10. doi:10.1371/journal.pone.0035793
Cervantes F, Hernández-Boluda JC, Villamor N, Serra A, Montserrat E (2000) Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol 65:104–108. doi:10.1034/j.1600-0609.2000.90262.x
Elia F, Villani S, Ambrogi S, Signorini L, Dallari S, Binda S, Primache V, Pellegrinelli L, Ferrante P, Delbue S (2016) JC virus infection is acquired very early in life: evidence from a longitudinal serological study. J Neuro-Oncol 23:99–105. doi:10.1007/s13365-016-0477-9
Jelcic I, Jelcic I, Faigle W, Sospedra M, Martin R (2015) Immunology of progressive multifocal leukoencephalopathy. J Neuro-Oncol 21:614–622. doi:10.1007/s13365-014-0294-y
Martí-Carvajal AJ, Anand V, Solà I (2015) Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis (review). The Cochrane Library issue 4, art No : CD010298. doi: 10.1002/14651858.CD010298.pub2
Miskin DP, Koralnik IJ (2015) Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area. Curr Opin Neurol 28:288–294. doi:10.1097/WCO.0000000000000201
Molica M, Serrao A, Saracino R, Zacheo I, Stingone C, Alimena G, Breccia M (2014) Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? Ann Hematol 93:1951–1952. doi:10.1007/s00277-014-2096-y
Moro-García M, Alonso-Arias R, López-Vazquez A, Suárez-García FM, Solano-Jaurrieta JJ, Baltar J, López-Larrea C (2012) Relationship between functional ability in older people, immune system status, and intensity of response to CMV. Age 34:479–495. doi:10.1007/s11357-011-9240-6
O’Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161–170. doi:10.1056/NEJMra1202117
Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML. Neurology 88:1197–1205. doi:10.1212/WNL.0000000000003739
Wather R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369:197. doi:10.1056/NEJMc1302135
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Ballesta, B., González, H., Martín, V. et al. Fatal ruxolitinib-related JC virus meningitis. J. Neurovirol. 23, 783–785 (2017). https://doi.org/10.1007/s13365-017-0558-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-017-0558-4